

Jerome de Seze

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5840243/jerome-de-seze-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274
papers

18,570
citations

62
h-index

130
g-index

323
ext. papers

22,048
ext. citations

5.8
avg, IF

6.18
L-index

#	Paper	IF	Citations
274	CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. <i>Immuno</i> , 2022 , 2, 118-131		0
273	Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
272	Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
271	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	0
270	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.. <i>Lancet Neurology</i> , 2022 ,	24.1	4
269	Emotional experience is increased and emotion recognition decreased in multiple sclerosis. <i>Scientific Reports</i> , 2021 , 11, 21885	4.9	0
268	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021 , 4, e2128271	10.4	3
267	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1556-1563	5	2
266	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 729-741	5	3
265	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021 , 48, 170-175	3.1	3
264	Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. <i>Neurology</i> , 2021 , 96, e2006-e2015	6.5	4
263	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	21
262	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103080	4	2
261	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103076	4	3
260	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
259	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1
258	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , 2021 , 20, 762-772	14	37

257	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 55, 103164	4	1
256	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020 , 10, e035397	3	5
255	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1079-1088	17.2	235
254	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020 , 17, 128	10.1	5
253	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. <i>Revue Neurologique</i> , 2020 , 176, 100-112	3	6
252	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
251	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	40
250	Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 118-122	5	34
249	Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). <i>PLoS ONE</i> , 2019 , 14, e0211465	3.7	7
248	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
247	Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. <i>Analyst</i> , 2019 , 144, 4647-4652	5	10
246	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019 , 266, 1743-1755	5.5	5
245	FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 54	10.1	8
244	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319836664	2	15
243	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019 , 93, e635-e646	6.5	24
242	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019 , 16, 134	10.1	66
241	Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study. <i>Cortex</i> , 2019 , 117, 205-216	3.8	6
240	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019 , 381, 2114-2124	59.2	212

239	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 109-116	4	4
238	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019 , 266, 806-815	5.5	27
237	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. <i>Current Opinion in Neurology</i> , 2019 , 32, 111-114	7.1	5
236	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. <i>Drugs</i> , 2019 , 79, 125-142	12.1	36
235	Ozone, NO and PM are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. <i>Environmental Research</i> , 2018 , 163, 43-52	7.9	33
234	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. <i>Neurology</i> , 2018 , 90, e1858-e1869	6.5	268
233	Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study. <i>Neuropsychological Rehabilitation</i> , 2018 , 28, 1110-1130	3.1	11
232	An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies. <i>Journal of Autoimmunity</i> , 2018 , 92, 114-125	15.5	14
231	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 132-136	5.5	108
230	Air pollution by particulate matter PM may trigger multiple sclerosis relapses. <i>Environmental Research</i> , 2017 , 156, 404-410	7.9	44
229	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. <i>Current Treatment Options in Neurology</i> , 2017 , 19, 19	4.4	3
228	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e346	9.1	9
227	Autophagy in neuroinflammatory diseases. <i>Autoimmunity Reviews</i> , 2017 , 16, 856-874	13.6	34
226	Radiologically isolated syndrome in children: Clinical and radiologic outcomes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e395	9.1	24
225	Thfapeutiques et prise en charge de la sclérose en plaques 2017 , 145-216		1
224	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017 , 12, e0168834	3.7	15
223	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
222	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1377-1384	5	59

221	MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?. <i>Brain</i> , 2017 , 140, 3072-3075	7.5	7
220	Diagnostiques différentiels de la sclérose en plaques 2017 , 113-143		
219	Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies. <i>Cells</i> , 2017 , 6,	7.9	9
218	Signes et symptômes de la sclérose en plaques 2017 , 3-78		
217	Diagnostic positif de la sclérose en plaques 2017 , 79-111		
216	Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. <i>Joint Bone Spine</i> , 2016 , 83, 330-4	2.9	4
215	Distinct and common cerebral activation changes during mental time travel in relapsing-remitting multiple sclerosis patients. <i>Brain Imaging and Behavior</i> , 2016 , 10, 296-313	4.1	2
214	Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months. <i>Clinical Neuropharmacology</i> , 2016 , 39, 188-93	1.4	15
213	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	4.0	27.1
212	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016 , 30, 41-51	6.7	19
211	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 93-96	4	8
210	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016 , 86, 771-8	6.5	57
209	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 69-76	3.2	32
208	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016 , 263, 140-9	5.5	4.0
207	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 955-9	5	47
206	Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. <i>Brain and Cognition</i> , 2016 , 105, 34-45	2.7	12
205	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1231-4	5	9
204	An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 180-8	6.6	37

203	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1719-1731	5	201
202	Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients. <i>Consciousness and Cognition</i> , 2016 , 45, 200-209	2.6	9
201	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015 , 85, 177-89	6.5	2255
200	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 390-3	3	17
199	Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study. <i>Revue Neurologique</i> , 2015 , 171, 407-14	3	1
198	Dalfampridine in hereditary spastic paraplegia: a prospective, open study. <i>Journal of Neurology</i> , 2015 , 262, 1285-8	5.5	13
197	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. <i>Journal of Neuroinflammation</i> , 2015 , 12, 46	10.1	112
196	Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. <i>Journal of Neurology</i> , 2015 , 262, 1637-45	5.5	19
195	MRI characteristics of neuromyelitis optica spectrum disorder: an international update. <i>Neurology</i> , 2015 , 84, 1165-73	6.5	404
194	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015 , 84, 1805-15	6.5	30
193	Neural correlates of episodic future thinking impairment in multiple sclerosis patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015 , 37, 1107-23	2.1	11
192	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e134	9.1	79
191	Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. <i>Journal of Neuroimmunology</i> , 2015 , 278, 1-10	3.5	13
190	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16
189	Functional cerebral changes in multiple sclerosis patients during an autobiographical memory test. <i>Memory</i> , 2015 , 23, 1123-39	1.8	7
188	Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study. <i>Restorative Neurology and Neuroscience</i> , 2015 , 33, 621-38	2.8	22
187	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015 , 72, 815-22	17.2	49
186	Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015 , 138, 284-92	11.2	41

185	OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. <i>Journal of Neuroradiology</i> , 2015 , 42, 133-40	3.1	42
184	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 678-88	5	172
183	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015 , 84, 1145-52	6.5	47
182	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015 , 10, e0132033	3.7	40
181	Immunological profiles determine neurological involvement in Sjögren's syndrome. <i>European Journal of Internal Medicine</i> , 2014 , 25, 177-81	3.9	35
180	Lyme neuroborreliosis and dementia. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 1087-93	4.3	24
179	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 822-9	5	52
178	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014 , 13, 197-205	13.6	61
177	Isolated anti-β ₂ -glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?. <i>European Journal of Neurology</i> , 2014 , 21, 901-6	6	5
176	Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 279-83	5.5	21
175	Chronic Bickerstaff's encephalitis with cognitive impairment, a reality?. <i>BMC Neurology</i> , 2014 , 14, 99	3.1	2
174	Impaired mental simulation of specific past and future personal events in non-depressed multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2014 , 345, 68-74	3.2	16
173	Multiple sclerosis and pregnancy. <i>Revue Neurologique</i> , 2014 , 170, 247-65	3	15
172	Relapsing optic neuritis: a multicentre study of 62 patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 848-53	5	23
171	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
170	Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 843-7	5	125
169	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141
168	Extensive cerebral white matter involvement in a patient with NMO spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1401-3	5	16

167	A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. <i>European Journal of Neurology</i> , 2014 , 21, 40-8	6	28
166	A case of recurrent facial pain associated with a Pourfour du Petit syndrome: a new entity?. <i>Headache</i> , 2014 , 54, 373-7	4.2	4
165	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. <i>JAMA Neurology</i> , 2014 , 71, 436-41	17.2	110
164	Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 558-65	5	32
163	Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. <i>BMC Neurology</i> , 2014 , 14, 215	3.1	2
162	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1086-94	5	66
161	No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 89-93	4	
160	Overview of treatment of NMO. <i>Acta Ophthalmologica</i> , 2014 , 92, 0-0	3.7	
159	Antibodies, MRI and unusual clinical features of NMO. <i>Acta Ophthalmologica</i> , 2014 , 92, 0-0	3.7	
158	Novel SPG10 mutation associated with dysautonomia, spinal cord atrophy, and skin biopsy abnormality. <i>European Journal of Neurology</i> , 2013 , 20, 398-401	6	9
157	Heroin inhalation-induced unilateral complete hippocampal stroke. <i>Neurocase</i> , 2013 , 19, 313-5	0.8	14
156	Recommendations for useful serum testing with suspected multiple sclerosis. <i>Revue Neurologique</i> , 2013 , 169, 37-46	3	6
155	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013 , 43, 60-9	15.5	123
154	Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. <i>Brain Pathology</i> , 2013 , 23, 647-60	6	29
153	The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach. <i>Journal of Neurology</i> , 2013 , 260, 3015-22	5.5	5
152	Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica. <i>Neuro-Ophthalmology</i> , 2013 , 37, 141-145	0.9	12
151	Autobiographical memory in multiple sclerosis patients: assessment and cognitive facilitation. <i>Neuropsychological Rehabilitation</i> , 2013 , 23, 161-81	3.1	24
150	Evaluation of new immunological targets in neuromyelitis optica. <i>Journal of Peptide Science</i> , 2013 , 19, 25-32	2.1	5

149	White matter volume is decreased in the brain of patients with neuromyelitis optica. <i>European Journal of Neurology</i> , 2013 , 20, 361-7	6	38
148	Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker?. <i>Lupus</i> , 2013 , 22, 229-32	2.6	7
147	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 922-30	5.5	112
146	Robotic-assisted thymectomy with Da Vinci II versus sternotomy in the surgical treatment of non-thymomatous myasthenia gravis: early results. <i>Revue Neurologique</i> , 2013 , 169, 30-6	3	15
145	Longitudinal change detection: inference on the diffusion tensor along white matter pathways. <i>Medical Image Analysis</i> , 2013 , 17, 375-86	15.4	5
144	Reduction of the washout time between natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1248	5	19
143	Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. <i>Neurology</i> , 2013 , 80, 2194-200	6.5	126
142	Prise en charge thérapeutique des manifestations neuropsychiatriques du lupus érythémateux 2013 , 265-271		
141	Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. <i>Neurology</i> , 2013 , 81, 206-10	6.5	5
140	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1320-2	5	23
139	Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 392-7	5.5	23
138	Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 979-86	5.1	3
137	Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 146219		19
136	Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome. <i>ISRN Neurology</i> , 2013 , 2013, 501327		14
135	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , 2012 , 11, 420-8	24.1	128
134	PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. <i>Epileptic Disorders</i> , 2012 , 14, 90-3	1.9	11
133	Recommendations for the detection and therapeutic management of cognitive impairment in multiple sclerosis. <i>Revue Neurologique</i> , 2012 , 168, 785-94	3	7
132	Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1135-43	5	88

131	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	40	827
130	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. <i>Journal of Neurology</i> , 2012 , 259, 2293-8	5.5	30
129	Atypical forms of optic neuritis. <i>Revue Neurologique</i> , 2012 , 168, 697-701	3	13
128	Diffusion tensor imaging of normal-appearing white matter in neuromyelitis optica. <i>Journal of Neuroradiology</i> , 2012 , 39, 295-300	3.1	23
127	Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 367, 1087-97	59.2	943
126	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 796-802	5.5	77
125	Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. <i>Muscle and Nerve</i> , 2012 , 46, 687-91	3.4	53
124	Inflammatory-like presentation of CADASIL: a diagnostic challenge. <i>BMC Neurology</i> , 2012 , 12, 78	3.1	12
123	Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2012 , 69, 1259-69		83
122	The Brown Norway opticospinal model of demyelination: does it mimic multiple sclerosis or neuromyelitis optica?. <i>International Journal of Developmental Neuroscience</i> , 2012 , 30, 487-97	2.7	10
121	Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors. <i>NeuroImage</i> , 2012 , 60, 2206-21	7.9	9
120	Treatment of Neuromyelitis Optica: Review and Recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 180-187	4	176
119	Review of Animal Models of Neuromyelitis Optica. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 174-179	4	13
118	Asthma as a cause of persistent dyspnea in treated myasthenia gravis patients. <i>European Neurology</i> , 2012 , 68, 300-3	2.1	3
117	Recommendations for the management of multiple sclerosis relapses. <i>Revue Neurologique</i> , 2012 , 168, 425-33	3	4
116	Recommendations for a definition of multiple sclerosis in support of early treatment. <i>Revue Neurologique</i> , 2012 , 168, 328-37	3	2
115	OPA3--related autosomal dominant optic atrophy and cataract with ataxia and areflexia. <i>European Neurology</i> , 2012 , 68, 108-10	2.1	13
114	Patient perceptions of multiple sclerosis and its treatment. <i>Patient Preference and Adherence</i> , 2012 , 6, 263-73	2.4	42

113	Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2012 , 259, 1215-21	5.5	14
112	Methionine synthase deficiency: a rare cause of adult-onset leukoencephalopathy. <i>Neurology</i> , 2012 , 79, 386-8	6.5	12
111	A case of paraneoplastic demyelinating motor polyneuropathy. <i>Case Reports in Neurology</i> , 2012 , 4, 71-6	1	9
110	Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 699-705	5.5	11
109	Induced brain plasticity after a facilitation programme for autobiographical memory in multiple sclerosis: a preliminary study. <i>Multiple Sclerosis International</i> , 2012 , 2012, 820240	1.1	27
108	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1297-302	5	48
107	Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. <i>Archives of Neurology</i> , 2012 , 69, 847-55		79
106	Long-term follow-up of acute partial transverse myelitis. <i>Archives of Neurology</i> , 2012 , 69, 357-62		31
105	Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. <i>Brain</i> , 2012 , 135, 2980-93	11.2	128
104	White matter atrophy and cognitive dysfunctions in neuromyelitis optica. <i>PLoS ONE</i> , 2012 , 7, e33878	3.7	69
103	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1067-73	5	126
102	Suicidal ideation in Huntington disease: the role of comorbidity. <i>Psychiatry Research</i> , 2011 , 188, 372-6	9.9	69
101	Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. <i>European Journal of Neurology</i> , 2011 , 18, 836-41	6	43
100	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. <i>Clinical Immunology</i> , 2011 , 138, 239-46	9	23
99	Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2011 , 77, 2128-34	6.5	155
98	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011 , 258, 1304-11	5.5	43
97	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1409-12	5.5	65
96	Current and future treatment approaches for neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2011 , 4, 111-21	6.6	64

95	Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 323-5	5.5	28
94	Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. <i>American Journal of Epidemiology</i> , 2011 , 174, 326-35	3.8	61
93	A benign form of neuromyelitis optica: does it exist?. <i>Archives of Neurology</i> , 2011 , 68, 918-24		44
92	Case 173: acute disseminated encephalomyelitis confined to the brainstem. <i>Radiology</i> , 2011 , 260, 911-4	20.5	3
91	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1344-50	5.5	62
90	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 720-4	5	16
89	Longitudinal change detection: inference on the diffusion tensor along white-matter pathways. <i>Lecture Notes in Computer Science</i> , 2011 , 14, 1-8	0.9	1
88	Neuromyelitis optica in France: a multicenter study of 125 patients. <i>Neurology</i> , 2010 , 74, 736-42	6.5	171
87	Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 409-11	5.5	44
86	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 919-25	5	90
85	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010 , 292, 28-35	3.2	50
84	Lyme optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010 , 295, 117-9	3.2	32
83	Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patients. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 286-90	2	13
82	A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 387-401	59.2	1971
81	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 87-92	5	33
80	POLG1 variations presenting as multiple sclerosis. <i>Archives of Neurology</i> , 2010 , 67, 1140-3		25
79	Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. <i>Journal of Neurology</i> , 2010 , 257, 207-11	5.5	33
78	Diffusion-weighted imaging in noncompressive myelopathies: a 33-patient prospective study. <i>Journal of Neurology</i> , 2010 , 257, 1438-45	5.5	29

77	Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. <i>Brain</i> , 2009 , 132, 2161-9	11.2	85
76	Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. <i>Journal of Immunology</i> , 2009 , 183, 4067-76	5.3	161
75	Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. <i>Archives of Neurology</i> , 2009 , 66, 841-6		145
74	Is neuromyelitis optica associated with human leukocyte antigen?. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 571-9	5	90
73	Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 593-600	5	9
72	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2009 , 256, 134-6	5.5	6
71	Long-term outcome of acute and subacute myelopathies. <i>Journal of Neurology</i> , 2009 , 256, 980-8	5.5	46
70	Foreign accent syndrome as a first sign of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1123-5	5	19
69	Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. <i>Cytokine</i> , 2009 , 45, 55-7	4	102
68	Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?. <i>Journal of the Neurological Sciences</i> , 2009 , 287, 69-71	3.2	56
67	An a contrario approach for outliers segmentation: Application to Multiple Sclerosis in MRI 2008 ,		4
66	NMO-IgG and Devic's neuromyelitis optica: a French experience. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 440-5		95
65	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 399-405	5	80
64	Neuromyelitis optica and non organ-specific autoimmunity. <i>Archives of Neurology</i> , 2008 , 65, 78-83		387
63	Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay. <i>Clinica Chimica Acta</i> , 2008 , 391, 98-101	6.2	4
62	Monophasic Acute, Recurrent, and Multiphasic Disseminated Encephalomyelitis and Multiple Sclerosis Reply. <i>Archives of Neurology</i> , 2008 , 65, 672		
61	Differential Diagnosis Between Acute Disseminated Encephalomyelitis and Multiple Sclerosis During the First Episode Reply. <i>Archives of Neurology</i> , 2008 , 65, 672		
60	Relapsing inflammatory optic neuritis: is it neuromyelitis optica?. <i>Neurology</i> , 2008 , 70, 2075-6	6.5	40

59	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 195-8	5.5	92
58	Multiple Sclerosis and Recurrent Disseminated Encephalomyelitis Are Different Diseases Reply. <i>Archives of Neurology</i> , 2008 , 65, 672		
57	Cognitive functions in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 84-8		86
56	Optical coherence tomography in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 920-3		83
55	Relapsing demyelinating disease affecting both the central and peripheral nervous systems. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 1032-9	5.5	38
54	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3420-32		44
53	Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. <i>European Journal of Neurology</i> , 2007 , 14, 85-9	6	34
52	Obstructive sleep apnoea: an underestimated cause of peripheral neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 222	5.5	3
51	Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. <i>Neurology</i> , 2007 , 69, 953-8	6.5	117
50	An a contrario approach for change detection in 3D multimodal images: application to multiple sclerosis in MRI. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2007 , 2007, 2069-72		7
49	Acute fulminant demyelinating disease: a descriptive study of 60 patients. <i>Archives of Neurology</i> , 2007 , 64, 1426-32		117
48	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 256-9	5	161
47	Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 622-5	5	11
46	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006 , 179, 53-64	3.5	23
45	Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. <i>Neurology</i> , 2006 , 67, 1684-6	6.5	19
44	Unusual ocular motor findings in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006 , 243, 91-5	3.2	35
43	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Immunology Letters</i> , 2005 , 96, 11-26	4.1	56
42	Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. <i>Immunology Letters</i> , 2005 , 97, 55-62	4.1	8

41	Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. <i>Neurology</i> , 2005 , 65, 1950-3	6.5	122
40	Association of multiple sclerosis with ILT6 deficiency. <i>Genes and Immunity</i> , 2005 , 6, 445-7	4.4	44
39	Mycophenolate mofetil and neurological diseases. <i>Lupus</i> , 2005 , 14 Suppl 1, s42-5	2.6	13
38	Man-in-the-barrel syndrome caused by a pontine lesion. <i>Neurology</i> , 2005 , 64, 1703	6.5	10
37	Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 395-7	5	13
36	One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 360-3	5	28
35	Autoimmune hepatitis and multiple sclerosis: a coincidental association?. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 691-3	5	36
34	Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 92	5	19
33	Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. <i>Medicine (United States)</i> , 2004 , 83, 280-291	1.8	401
32	Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. <i>Journal of Immunology</i> , 2004 , 172, 669-78	5.3	41
31	Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 596-7	5	74
30	CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. <i>European Journal of Neurology</i> , 2004 , 11, 525-9	6	56
29	New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. <i>Proteomics</i> , 2004 , 4, 2184-94	4.8	60
28	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 73-7	3.2	51
27	Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charcot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. <i>Neuromuscular Disorders</i> , 2004 , 14, 261-4	2.9	30
26	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 521-5	5	103
25	Double-blind crossover study with dolasetron mesilate, a 5-HT ₃ receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1190-4	5.5	16
24	Prospective study of patients presenting with acute partial transverse myelopathy. <i>Journal of Neurology</i> , 2003 , 250, 1447-52	5.5	54

23	Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2003 , 27, 497-9	3.4	22
22	Multiple sclerosis, interferon beta and clinical thyroid dysfunction. <i>Acta Neurologica Scandinavica</i> , 2003 , 107, 154-7	3.8	18
21	Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. <i>Clinical Neurophysiology</i> , 2003 , 114, 1609-14	4.3	34
20	Multiple sclerosis and depression: influence of interferon beta therapy. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 284-8	5	51
19	Neuromyelitis optica. <i>Archives of Neurology</i> , 2003 , 60, 1336-8		24
18	Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome. <i>Journal of Neuroimmunology</i> , 2002 , 129, 232	3.5	2
17	14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. <i>Journal of Neurology</i> , 2002 , 249, 626-7	5.5	21
16	Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. <i>Journal of Neurology</i> , 2002 , 249, 184-7	5.5	9
15	Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 377-81	5	58
14	DevicB neuromyelitis optica: clinical, laboratory, MRI and outcome profile. <i>Journal of the Neurological Sciences</i> , 2002 , 197, 57-61	3.2	153
13	Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. <i>American Journal of Human Genetics</i> , 2002 , 71, 492-500	11	338
12	Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. <i>Journal of Neurology</i> , 2001 , 248, 672-5	5.5	25
11	Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. <i>Journal of Neurology</i> , 2001 , 248, 297-303	5.5	40
10	IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001 , 117, 149-55	3.5	33
9	Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. <i>Brain</i> , 2001 , 124, 1509-21	11.2	142
8	Molecular analysis of endogenous retrovirus HRES-1: identification of frameshift mutations in region encoding putative 28-kDa autoantigen. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 283, 437-44	3.4	4
7	Pupillary disturbances in multiple sclerosis: correlation with MRI findings. <i>Journal of the Neurological Sciences</i> , 2001 , 188, 37-41	3.2	33
6	Cardiac repolarization abnormalities in multiple sclerosis: spinal cord MRI correlates. <i>Muscle and Nerve</i> , 2000 , 23, 1284-6	3.4	10

5	Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. <i>Acta Neurologica Scandinavica</i> , 2000 , 101, 311-4	3.8	1
4	Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis. <i>Journal of Neurology</i> , 2000 , 247, 478-80	5.5	21
3	Atypical form of non-Langerhans histiocytosis with disseminated brain and leptomeningeal lesions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 675-8	5.5	9
2	Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2000 , 111, 2285-91	4.3	33
1	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France		18